Dynamic Advisor Options LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.5% within the third quarter, in accordance with the corporate in its most up-to-date submitting with the SEC. The agency owned 103,378 shares of the biopharmaceutical firm’s inventory after promoting 1,525 shares throughout the quarter. Dynamic Advisor Options LLC’s holdings in Pfizer had been price $2,992,000 as of its most up-to-date SEC submitting.
A number of different massive buyers additionally not too long ago modified their holdings of the inventory. Wasatch Advisors LP raised its holdings in shares of Pfizer by 21.0% throughout the 4th quarter. Wasatch Advisors LP now owns 167,300 shares of the biopharmaceutical firm’s inventory price $4,817,000 after shopping for an extra 29,000 shares within the final quarter. Icon Wealth Advisors LLC purchased a brand new place in shares of Pfizer within the fourth quarter price about $479,000. Redwood Funding Administration LLC boosted its stake in shares of Pfizer by 1.8% within the 4th quarter. Redwood Funding Administration LLC now owns 81,252 shares of the biopharmaceutical firm’s inventory valued at $2,339,000 after buying an extra 1,465 shares within the final quarter. Pinnacle Holdings LLC grew its holdings in shares of Pfizer by 24.0% throughout the 4th quarter. Pinnacle Holdings LLC now owns 6,712 shares of the biopharmaceutical firm’s inventory valued at $193,000 after buying an extra 1,300 shares over the last quarter. Lastly, New England Asset Administration Inc. elevated its place in Pfizer by 1.6% throughout the 4th quarter. New England Asset Administration Inc. now owns 170,098 shares of the biopharmaceutical firm’s inventory price $4,897,000 after buying an extra 2,743 shares within the final quarter. 68.36% of the inventory is owned by institutional buyers and hedge funds.
Analyst Rankings Adjustments
Numerous analysts have weighed in on the inventory. Cantor Fitzgerald reaffirmed an “obese” ranking and set a $45.00 goal worth on shares of Pfizer in a analysis observe on Thursday, October third. UBS Group boosted their worth goal on Pfizer from $30.00 to $31.00 and gave the inventory a “impartial” ranking in a analysis report on Wednesday, July thirty first. StockNews.com upgraded Pfizer from a “maintain” ranking to a “purchase” ranking in a analysis report on Wednesday. Wells Fargo & Firm boosted their worth goal on Pfizer from $28.00 to $30.00 and gave the inventory an “equal weight” ranking in a report on Wednesday, July thirty first. Lastly, Daiwa Capital Markets upgraded shares of Pfizer from a “impartial” ranking to an “outperform” ranking and lifted their goal worth for the inventory from $28.00 to $34.00 in a analysis report on Wednesday, August seventh. Eight analysis analysts have rated the inventory with a maintain ranking, seven have issued a purchase ranking and one has given a robust purchase ranking to the corporate. In keeping with MarketBeat.com, the inventory presently has a consensus ranking of “Average Purchase” and a mean goal worth of $34.54.
View Our Newest Inventory Report on PFE
Pfizer Buying and selling Up 3.5 %
NYSE:PFE opened at $30.20 on Thursday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week excessive of $33.92. The corporate has a debt-to-equity ratio of 0.65, a fast ratio of 0.60 and a present ratio of 0.86. The agency’s fifty day transferring common is $29.09 and its 200-day transferring common is $28.35. The agency has a market cap of $171.10 billion, a P/E ratio of -503.25, a P/E/G ratio of 1.23 and a beta of 0.67.
Pfizer (NYSE:PFE – Get Free Report) final issued its quarterly earnings outcomes on Tuesday, July thirtieth. The biopharmaceutical firm reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a detrimental web margin of 4.66% and a optimistic return on fairness of 8.42%. The enterprise had income of $13.28 billion for the quarter, in comparison with analysts’ expectations of $12.96 billion. Throughout the identical quarter within the prior 12 months, the agency posted $0.67 earnings per share. The enterprise’s quarterly income was up 2.1% in comparison with the identical quarter final 12 months. Equities analysts count on that Pfizer Inc. will submit 2.66 earnings per share for the present 12 months.
Pfizer Broadcasts Dividend
The agency additionally not too long ago declared a quarterly dividend, which might be paid on Monday, December 2nd. Shareholders of file on Friday, November eighth might be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.56%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.
Pfizer Firm Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical merchandise in america, Europe, and internationally. The corporate gives medicines and vaccines in varied therapeutic areas, together with cardiovascular metabolic, migraine, and girls’s well being underneath the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin household manufacturers; infectious illnesses with unmet medical wants underneath the Prevnar household, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba manufacturers; and COVID-19 prevention and remedy, and potential future mRNA and antiviral merchandise underneath the Comirnaty and Paxlovid manufacturers.
Beneficial Tales
Need to see what different hedge funds are holding PFE? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Obtain Information & Rankings for Pfizer Day by day – Enter your e-mail deal with under to obtain a concise every day abstract of the most recent information and analysts’ scores for Pfizer and associated firms with MarketBeat.com’s FREE every day e-mail e-newsletter.
